An early success with its cystic fibrosis gene therapy brings the company up.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Full Dupixent data confirm the drug’s blockbuster potential in the lung disease, but the French drug maker is thinking even bigger.
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Early clinical data with an inhaled RNA interference candidate look promising, but there is still much to prove.